三友化工(600409.SH):擬19.62億元投建年產4萬噸氯化亞碸、年產5萬噸氯乙酸、年產9.8萬噸燒鹼項目
格隆匯7月19日丨三友化工(600409.SH)公佈,公司全資子公司唐山三友精細化工有限公司(稱“精細化工公司”)擬依託曹妃甸大港口、國家石化基地等優勢,在曹妃甸工業區化學工業園區投資建設年產4萬噸氯化亞碸、年產5萬噸氯乙酸、年產9.8萬噸燒鹼項目,報批總投資19.62億元,其中約40%為自籌資金,其餘為銀行貸款資金。
本項目產品種類豐富,各類產品市場需求量增長迅速,應用範圍逐年擴展,廣泛用於醫藥、日常生活、工業農業等諸多行業,前景廣闊。項目建設投產後,可為國內外客户提供優質的產品,滿足不斷擴大的市場需求,打造公司新的利潤增長極。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.